Shuli Yi

机构：Kelun Group (China)

发表论文 9 篇 · 总被引 182 次 · h-index 6

代表论文

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours (2023 · npj Breast Cancer · 被引 55)
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer (2017 · Signal Transduction and Targeted Therapy · 被引 44)
Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models (2017 · Oncotarget · 被引 28)
Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. (2021 · Journal of Clinical Oncology · 被引 24)
Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy (2008 · Journal of Clinical Oncology · 被引 14)
Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. (2022 · Journal of Clinical Oncology · 被引 7)